Last December 2013 I asked Gerald at the Conference in L.A.

New Post Public Reply Private Reply Replies (1) Message Board
Daveludlow
Last December 2013 I asked Gerald at the Conference in L.A. if "shareholders would be happy by February." At that time we needed to get above .10 cents for 20 consecutive days in order to get the 5 or 10 million warrant money we needed to keep things going. Gerald responded, "Oh, we'll be in great shape by the U.N. Conference at the end of January." He further said they had a lot of catalysts coming after the first of the year.

It is true, in the first half of January the pps did spike up to .138 cents due to our anticipation of a LymPro Partnership. Many of us were expecting a JV partnership for Lympro with large up front money. Back in Sept of 2013 Gerald told me in Las Vegas regarding our LymPro partner: "Someone might pay you x now, but down the road be willing to pay you 100x." That is where I first got the notion of a "classic partner" for Lympro with up front money.

But at the SF Conference on January 15th, Gerald announced we had discovered some "codes" for reimbursement that would increase LymPro's net present value many times. And as a result, we would not be pursuing a Lympro partner in the immediate future. The stock price immediately started falling from .138 cents to below .07 cents. (Yet, I have never heard Gerald refer to these important codes since that occasion, nor seen the increase in net present value!)

The pps remained low until May when Gerald announced they had "identified" a Lympro partner but were still finalizing the details and wouldn't announcement the agreement until after the July Conferences in order to gain additional "leverage." The pps went from .07 cents to .193 cents on July 30th in anticipation of the LymPro data that preceded the LymPro partnership announcement. We all know what happened on July 31st. We dropped from .193 cents to .12 cents.

In August we held out hope for the LymPro data and the JV partnership announcement in September, the "end of summer." Instead, we got a master service agreement with ICON instead of a "classic partner" and the pps fell from .12 cents down to the .087 cents where we are now.

So, with all that said, many of us feel Gerald has left us at the altar a few times this year and as a result....feel anxiety over his promises that have managed to elusively slip away. During 2014.... we started at around .08 or .09 cents, and after many fits and starts....we are still there. So I would ask the people on the board who frequently lecture some of us longs that have criticisms....to be patient with us. Some of us are in a position where our investment is maybe larger than it should be for our overall net worth. As a result, we do care about the near term pps, not just what AMbS will be worth in 4 or 5 years. Please be patient with us and not lecture us about being over invested in this high risk stock. There are all sorts of people and situations and reasons why people invest the way they do.

The concerns I have raised this past month, and that JP has raised recently, and others as well, are not because we are flippers like Solantey, it is because we have genuine concerns. It doesn't mean we aren't solidly with you in our love of Gerald and belief in AMBS. We just have different expectations and time frames than you do.

Obviously, I sometimes get emotional and overstate things. I apologize for that. I will try to reign in the intensity. But my posts have been genuine. If dissenting and contrary views are presented on this board, in a polite way, they should be treated respectfully. I'll try not to call people names, if in return I am not belittled in posts attacking my concerns. It goes both ways.

I have been in stocks before that showed great promise, but never went anywhere. That is what happens in small biomed penny stocks. By the way, that is what we are! We're not Amgen yet. There are no guarantees that everything will turn out the way Gerald promises. They haven't so far. Many CEO's go down in flames trying to build their fledgling companies. So for those who are smug about AMBS' inevitability and like to lecture us who lack faith and like to question things....I ask that you not be so smug. You don't know but what our concerns may be valid. And the message board is the appropriate place to discuss them...civilly.


Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TCOM Secures $600M Deal to Boost NATO's Defense

Updated Category News Views 3

TCOM's Pivotal $600 Million Defense Contract How often do you hear about a deal north of $600 million that practically revamps a company's strategic future? That's precisely what's hitting the books at TCOM right now. They've scored a heavy-hitting Foreign Military Sales (FMS) contract to fortify NATO's eastern front with Poland. I'll tell you this—it’s one of the...

Continue Reading
Epson & The Photo Managers Highlight Memories in Sept.

Updated Category News Views 8

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 0

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading
MacGregor's Bold Play: RoRo Tech for TT-Line's Ferries

Updated Category News Views 2

A Green Wave in the Baltic It looks like MacGregor's betting big on the future of maritime transport, and they're putting their chips down on TT-Line's next-gen battery-hybrid LNG ferries. With a contract fresh out of the oven, they've signed up to kit out these eco-warriors with a range of RoRo equipment. And let me tell you, this is no piddly order—by any stretch,...

Continue Reading
Supercharged Entertainment's Big Bet in Ohio's Polaris

Updated Category News Views 0

Fasten your seatbelts, folks—because there's a tinge of burnt rubber in the air at Columbus's Polaris Center. Supercharged Entertainment, the big guns in indoor karting, just kicked off construction at their brand-new venue, and it’s looking like a gearhead's paradise. A sprawling 16-acre parcel is set to become a haven for adrenaline junkies come Summer 2027. A Bold...

Continue Reading
Immunic Pushes Boundaries in MS with Vidofludimus

Updated Category News Views 1

Shaking Things Up in Multiple Sclerosis Therapy There's no telling how often the biotech sector tosses around the term 'game-changer,' but when Immunic's name comes up, more ears are perking up these days. The New York-based firm, waving the Nasdaq: IMUX flag, is lining up a virtual shindig come September 9, 2026, and for anyone invested in multiple sclerosis (MS) or...

Continue Reading
Axjo Group Expands in France with Eco-Tourets Buy

Updated Category News Views 6

Seizing the French Market: Axjo's Strategic Play Every now and then, you come across a company that's not just talking the talk but walking the green walk. Axjo Group's latest move—scooping up France's Eco-Tourets—puts them squarely in that league. It ain't just about expanding the footprint; it's about owning a piece of the future where sustainability isn't a...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
Early Education's Massive Impact: Key Skills for Success

Updated Category News Views 2

Unlocking Lifelong Success: The Early Advantage Ever look at a successful adult and wonder, "Where'd they get that spark?" According to HelloNation and child care expert Karen Ego, it all starts early. Think of early learning not just as prepping for school, but as the first blueprint for life's journey. It's the skills you pick up in those tender years that stick it out...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 3

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading

Top 5 Most Recently Viewed Articles

Zealand Pharma A/S Updates Share Count and Voting Rights

Updated Category News Views 86

Zealand Pharma A/S, a key player in the biotech sector out of Copenhagen, confirmed back in early 2024 that it had a total of 71,023,871 shares outstanding. Each share carries a nominal value of DKK 1. This number isn’t just a footnote—it’s vital for any stakeholder keeping tabs on their stake or those considering diving into this space. The company’s compliance...

Continue Reading
CS Genetics Introduces Innovative SimpleCell™ Genomics Kits

Updated Category News Views 146

CS Genetics Launches SimpleCell™ for Enhanced Single-Cell Genomics Single-cell genomics has entered a new era with the exciting launch of SimpleCell™ 3' Gene Expression kits by CS Genetics, a pioneer in the field. This innovative platform simplifies the process of single-cell transcriptomics, making it more accessible and scalable than ever before. The Power of...

Continue Reading
LifeMD's Engagement at the Upcoming Growth Conference

Updated Category News Views 117

LifeMD's Participation in a Major Growth Conference LifeMD, Inc. (Nasdaq: LFMD), a prominent provider in the domain of virtual primary healthcare, has announced its upcoming participation in the Canaccord Genuity 45th Annual Growth Conference. This well-regarded event will take place from August 12 to 14, offering a dynamic platform for dialogue between investors and...

Continue Reading
Exploring Embedded Finance in India: Growth Forecasts to 2029

Updated Category News Views 306

The Future of Embedded Finance in India The embedded finance industry in India is on a remarkable growth trajectory. As we look ahead to the years leading up to 2029, projections indicate a compound annual growth rate (CAGR) of 37.8%, with revenue climbing from US$5.75 billion in 2024 to an impressive US$28.6 billion by the end of the forecast period. Transformative...

Continue Reading
Revolutionizing 3D Modeling: Fixstars Unveils CUMVS Software

Updated Category News Views 179

Revolutionizing 3D Modeling with CUMVS Software Fixstars Corporation, a leader in AI-driven software development, recently made waves with the open-source release of its groundbreaking software, CUMVS (cuda-multi-view-stereo), designed for rapid 3D model generation from 2D images. This innovative software allows users to create digital twins of real-world objects, marking...

Continue Reading